Mark Fogg

Mark Fogg has spent his career developing a deep understanding of the human immune response. From studying immunity to virus infections in academia to development of T cell therapies and antibodies to target cancer and autoimmunity.

After obtaining his PhD at the University of Reading in the UK, he spent 14 years in academia; initially at the NIAID/NIH followed by Brigham and Women's Hospital/Harvard Medical School. He then moved to industry with a focus on antibody therapeutics, leading a biomarker discovery team at Pfizer and as head of the immunology group at Abzena.

Mark then moved to Merus where he was responsible for multiple bispecific antibody discovery programs in immune oncology before joining Zymeworks and AbCellera as an immunology/antibody expert on the partnering team.